

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2022/182574 A1

(43) International Publication Date
01 September 2022 (01.09.2022)

(51) International Patent Classification:

C12N 15/113 (2010.01) *A61P 3/08* (2006.01)
A61K 31/713 (2006.01) *A61P 13/12* (2006.01)
A61P 3/06 (2006.01)

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2022/016890

(22) International Filing Date:

18 February 2022 (18.02.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/154,005 26 February 2021 (26.02.2021) US
63/223,581 20 July 2021 (20.07.2021) US
63/280,668 18 November 2021 (18.11.2021) US

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(71) Applicant: **ALNYLAM PHARMACEUTICALS, INC.**

[US/US]; 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA 02142 (US).

(72) Inventors; and

(71) Applicants: **NOETZLI, Leila** [US/US]; 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA 02142 (US). **MCININCH, James, D.** [US/US]; 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA 02142 (US). **TREMBLAY, Frederic** [CA/US]; 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA 02142 (US). **SCHLEGEL, Mark, K.** [US/US]; 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA 02142 (US). **CASTORENO, Adam** [US/US]; 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA 02142 (US).

(74) Agent: **ZACHARAKIS, Maria, Laccotripe** et al.; Mc-

Carter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,

(54) Title: KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

(57) Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the ketohexokinase (KHK) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a KHK gene and to methods of treating or preventing a KHK-associated disorder in a subject.

WO 2022/182574 A1